After Versanis success, Aditum launches Celexor Bio with autoimmune drug from Acelyrin partner Inmagene

The biotech licensing whizzes at Aditum Bio, the VC firm from ex-Novartis CEO Joe Jimenez and Mark Fishman, have created their 10th company by nabbing the rights to a preclinical autoimmune drug.

The new startup, Celexor Bio, will pay an undisclosed upfront and up to $287 million in biobucks to San Diego-based Inmagene Biopharmaceuticals, which will also get an equity stake in the new biotech and potential royalties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Step-by-step restart of IT systems – Biotech Investments

aap Implantate AG / Key word(s): Miscellaneous aap Implantate AG: Step-by-step restart of IT systems 18-Oct-2024 / 22:14 CET/CEST Disclosure of an inside information acc.

October 19, 2024

Medical device maker Teleflex to acquire urology company Palette Life Sciences for $600 million

Teleflex announced plans on Wednesday to acquire Palette Life Sciences, the maker of a slate of gel-based products treating urological disorders. The vascular device manufacturer

July 26, 2023

PsA Raises Mortality Risk, but Unevenly

Swedes with psoriatic arthritis (PsA) tended to die earlier than other people, a national case-control study indicated, but the risk varied considerably among different subgroups.

December 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.